SuperworthElanco Animal Health EPS ELAN
Diluted earnings per share by quarter and over the last twelve months, from 2017.
- Last 12 months, to Jun 30, 2026
- −$0.41
- Latest quarter, Q2 FY26
- $0.11
- +450% on a year earlier
- Fiscal year 2025
- −$0.48
- −172% on the year before
Elanco Animal Health's earnings per share was −$0.41 over the twelve months to Jun 30, 2026, down 148% on a year earlier.
In its latest quarter, Q2 FY26, it was $0.11, up 450% on the same quarter a year before.
Earnings per share over time
Fiscal year by fiscal year
| Fiscal year | EPS | Change |
|---|---|---|
| FY2025 | −$0.48 | −172% |
| FY2024 | $0.67 | n/a |
| FY2023 | −$2.50 | n/a |
| FY2022 | −$0.16 | n/a |
| FY2021 | −$0.99 | n/a |
| FY2020 | −$1.20 | −732% |
| FY2019 | $0.19 | −32% |
| FY2018 | $0.28 | n/a |
| FY2017 | −$1.06 | n/a |
Each fiscal year is the twelve months to its fourth quarter.
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier | Last 12 months |
|---|---|---|---|---|
| Q2 FY26 | $0.11 | +450% | −$0.41 | |
| Q1 FY26 | $0.11 | −15% | −$0.50 | |
| Q4 FY25 | −$0.56 | n/a | −$0.48 | |
| Q3 FY25 | −$0.07 | −110% | $0.06 | |
| Q2 FY25 | $0.02 | n/a | $0.86 | |
| Q1 FY25 | $0.13 | +117% | $0.74 | |
| Q4 FY24 | −$0.02 | n/a | $0.67 | |
| Q3 FY24 | $0.73 | n/a | $0.40 | |
| Q2 FY24 | −$0.10 | n/a | −$2.55 | |
| Q1 FY24 | $0.06 | −71% | −$2.65 | |
| Q4 FY23 | −$0.29 | n/a | −$2.50 | |
| Q3 FY23 | −$2.22 | n/a | −$2.32 |
Against its peers
Companies in Drug Manufacturers - General nearest Elanco Animal Health's size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| ELANElanco Animal Health | −$0.41 | −148% a year |
| BMRNBiomarin Pharmaceutical | $0.37 | −89% a year |
| CORTCorcept Therapeutics | $0.42 | −63% a year |
| JAZZJazz Pharmaceuticals | $14.62 | |
| PTGXProtagonist Therapeutics | $1.03 | +47% a year |
| TGTXTG Therapeutics | $2.74 | +641% a year |
| ALKSAlkermes plc. | $0.38 | −82% a year |
| AMRXAmneal Pharmaceuticals | $0.49 | +4800% a year |
| LGNDLigand Pharmaceuticals | $9.40 | |
| KNSAKiniksa Pharmaceuticals International | $0.97 | +2325% a year |
| INDVIndivior Pharmaceuticals | $2.78 | +227% a year |
| Peer median | $1.00 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Elanco Animal Health
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.